This international prize, established in 2002, encourages the work of promising young neurobiologists by providing support in the early stages of their careers. It is awarded annually for the most outstanding neurobiological research by a young scientist, as described in a 1,000-word essay based on research performed during the past three years.
The winner will receive US$25,000 and publication of his or her essay in Science. The essays of up to three finalists will also be published on Science Online.
Researchers who are 35 or younger are invited to apply by 15 June. The prizewinner will be selected by a committee of independent experts in the field, chaired by Science’s senior editor, Peter Stern.
The 2010 prize was won by Christopher Gregg, Postdoctoral Fellow at Harvard University for his research on maternal and paternal gene expression in the brain.
2011 Neurobiology Prize open for entries
Organised by Eppendorf and Science journal
You may also like
Research & Development
ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development
Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease
Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists